Cargando...

Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

Background: Triple negative breast carcinomas (TNBC) do not benefit from hormonal or Herceptin therapies. In search of novel therapeutic targets for TNBC, interest is escalating in a subset of these tumors that are androgen receptor (AR) positive with potential benefit from anti-androgen therapy. Ag...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Safarpour, Damoun, Pakneshan, Shabnam, Tavassoli, Fattaneh A
Formato: Artigo
Lenguaje:Inglês
Publicado: e-Century Publishing Corporation 2014
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4106653/
https://ncbi.nlm.nih.gov/pubmed/25057438
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!